Multippel Sklerose

Vitenskapelig artikkel

• Tilde Harridsleff Rasmussen; Stine Schikora-Rustad; Åslaug Rudjord Lorentzen et al. (2026). Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study. (ekstern lenke)
• Shamundeeswari Anandan; Karina Maciak; Regina Breinbauer et al. (2025). In-Depth Characterization of L1CAM+ Extracellular Vesicles as Potential Biomarkers for Anti-CD20 Therapy Response in Relapsing–Remitting Multiple Sclerosis. (ekstern lenke)
• Hilde Norborg; Jan Harald Aarseth; Janne Mannseth et al. (2025). Effect of early highly effective treatment compared to an escalating treatment strategy in multiple sclerosis. (ekstern lenke)
• Akash Kapali; Anne Kjersti Nesje Daltveit; Kjell-Morten Myhr et al. (2025). Vitamin D intake and multiple sclerosis risk in the Norwegian Mother, Father and Child cohort. (ekstern lenke)
• Max Korbmacher; Ingrid Anne Lie; Kristin Wesnes et al. (2025). Multimodal predictors of disability progression and processing speed decline in relapsing–remitting multiple sclerosis. (ekstern lenke)
• Solveig B Glad; Harald Inge Nyland; Jan Harald Aarseth et al. (2011). How long can you keep working with benign multiple sclerosis?. (ekstern lenke)
• Kjetil Bjørnevik; Trond Riise; Espen Benjaminsen et al. (2017). Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. (ekstern lenke)
• Alok Bhan; Cecilie Jacobsen; Kjell-Morten Myhr et al. (2018). Neurofilaments and 10-year follow-up in multiple sclerosis. (ekstern lenke)
• Ragnhild Reehorst Lereim; Eystein Oveland; Y. Xiao et al. (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. (ekstern lenke)
• Kjell-Morten Myhr; Nina Agnethe Grytten; Jan Harald Aarseth (2012). The Norwegian Multiple Sclerosis Registry and Biobank. (ekstern lenke)
• Øivind Torkildsen; Nina Agnethe Grytten; Jan Harald Aarseth et al. (2012). Month of birth as a risk factor for multiple sclerosis: an update. (ekstern lenke)
• M Pugliatti; D. Eskic; T Mikolcic et al. (2012). Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. (ekstern lenke)
• Kjell-Morten Myhr (2006). Multippel sklerose. (ekstern lenke)
• Kristin Ingeleiv Løken; Kjell-Morten Myhr; Jacob Bakke et al. (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. (ekstern lenke)
• Ann Cathrine Kroksveen; Astrid Guldbrandsen; Marc Vaudel et al. (2017). In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. (ekstern lenke)
• Astrid Guldbrandsen; Yehia Mohamed Mokhtar Farag; Ann Cathrine Kroksveen et al. (2016). CSF-PR 2.0: an interactive literature guide to quantitative cerebrospinal fluid mass spectrometry data from neurodegenerative disorders. (ekstern lenke)
• Trygve Holmøy; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. (ekstern lenke)
• Solveig Bergliot Glad; Jan Harald Aarseth; Harald Inge Nyland et al. (2010). Benign multiple sclerosis: a need for a consensus. (ekstern lenke)
• Inger-Lise Mero; Maria Ban; Åslaug Rudjord Lorentzen et al. (2011). Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus. (ekstern lenke)
• Tori Smedal; Kjell-Morten Myhr; Jan Harald Aarseth et al. (2010). The influence of warm versus cold climate on the effect of physiotherapy in multiple sclerosis. (ekstern lenke)
• Marianna Cortese; Trond Riise; Kjetil Lauvland Bjørnevik et al. (2015). Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study.. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Trond Riise; Marianna Cortese et al. (2015). Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. (ekstern lenke)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2021). Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study. (ekstern lenke)
• Ann Cathrine Kroksveen; Jill Anette Opsahl; Astrid Guldbrandsen et al. (2015). Cerebrospinal fluid proteomics in multiple sclerosis. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2024). Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women. (ekstern lenke)
• Julie Dahl; Kjell-morten Myhr; Anne Kjersti Nesje Daltveit et al. (2006). Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. (ekstern lenke)
• Cecilie Osman Jacobsen; Jesper Hagemeier; Kjell-Morten Myhr et al. (2014). Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. (ekstern lenke)
• HF Harbo; BA Lie; S Sawcer et al. (2004). Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. (ekstern lenke)
• Kristin Wesnes; Kjell-Morten Myhr; Trond Riise et al. (2021). Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. (ekstern lenke)
• Nanna Figved; Kjell-Morten Myhr; Jan Petter Larsen et al. (2007). Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. (ekstern lenke)
• Karine Eid; Øivind Fredvik Grytten Torkildsen; Jan Harald Aarseth et al. (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. (ekstern lenke)
• Sigurgeir Olafsson; S. Olafsson; Pernilla Stridh et al. (2017). Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. (ekstern lenke)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2019). Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. (ekstern lenke)
• Ellen Færgestad Mosleth; Christian Alexander Vedeler; Kristian Hovde Liland et al. (2021). Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. (ekstern lenke)
• Sonia Gavasso; Ellen Færgestad Mosleth; Tove Helene Marøy et al. (2014). Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. (ekstern lenke)
• Kirsten Lode; J.P. Larsen; Edvin Bru et al. (2007). Patient information and coping styles in multiple sclerosis. (ekstern lenke)
• Marianna Cortese; Trond Riise; Kjetil Lauvland Bjørnevik et al. (2017). Body size and physical exercise, and the risk of multiple sclerosis. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2018). Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. (ekstern lenke)
• Kristin Nielsen Varhaug; Christian Barro; Kjetil Lauvland Bjørnevik et al. (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. (ekstern lenke)
• Frode Berven; Ann Cathrine Kroksveen; Magnus Foldal Berle et al. (2007). Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. (ekstern lenke)
• Nina Grytten; Anne Britt Skår; Jan Harald Aarseth et al. (2016). The influence of coping styles on long-term employment in multiple sclerosis: A prospective study. (ekstern lenke)
• Øyvind Torkildsen; Egil Utsi; Hanne F. Harbo et al. (2005). Ethnic Variations of IL-10 Polymorphisms in a Sami and Norwegian Population. (ekstern lenke)
• Øyvind Torkildsen; Egil Utsi; Svein Ivar Mellgren et al. (2005). Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. (ekstern lenke)
• Julie Dahl; Kjell-Morten Myhr; Anne Kjersti Daltveit et al. (2006). Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). The cuprizone model: regional heterogeneity of pathology. (ekstern lenke)
• Espen Benjaminsen; Kjell-Morten Myhr; Nina Agnethe Grytten Torkildsen et al. (2020). Comorbidity in multiple sclerosis patients from Nordland County, Norway - validated data from the Norwegian Patient Registry. (ekstern lenke)
• Åslaug Rudjord Lorentzen; Elisabeth Gulowsen Celius; Per Olaf Ekstrøm et al. (2005). Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. (ekstern lenke)
• AG Beiske; H Naess; JH Aarseth et al. (2007). Health-related quality of life in secondary progressive multiple sclerosis. (ekstern lenke)
• HF Harbo; E Utsi; Åslaug Rudjord Lorentzen et al. (2007). Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. (ekstern lenke)
• AG Beiske; H Naess; JH Aarseth et al. (2006). Health-related quality of life in secondary progressive multiple sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Per Knappskog; Harald Inge Nyland et al. (2008). Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. (ekstern lenke)
• Reidar Arneberg; Tarja Rajalahti; Kristian Flikka et al. (2007). Pretreatment of mass spectral profiles: Application to proteomic data. (ekstern lenke)
• Trygve Holmøy; Qin Ying Esbensen; Øivind Torkildsen et al. (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study.. (ekstern lenke)
• Kristin Varhaug; Christian A. Vedeler; Kjell-Morten Myhr et al. (2016). Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. (ekstern lenke)
• Frank Riemer; Ellen Skorve; Ofer Pasternak et al. (2023). Microstructural changes precede depression in patients with relapsing-remitting Multiple Sclerosis. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (1999). Quality of life in multiple sclerosis: Measuring the disease effects more broadly. (ekstern lenke)
• Giancarlo Comi; Vittorio Martinelli; Mariaemma Rodegher et al. (2013). Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. (ekstern lenke)
• O Torkildsen; Øivind Fredvik Torkildsen; Egil Utsi et al. (2005). Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. (ekstern lenke)
• Alok Bhan; Cecilie Jacobsen; Ingvild Dalen et al. (2021). CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis. (ekstern lenke)
• Sandra Magalhaes; Maura Pugliatti; Trond Riise et al. (2018). Shedding light on the link between early life sun exposure and risk of multiple sclerosis: results from the EnvIMS Study. (ekstern lenke)
• Nanna Figved; Gry Klevan; Kjell-Morten Myhr et al. (2005). Neuropsychiatric symptoms in patients with multiple sclerosis. (ekstern lenke)
• N Figved; R Benedict; G Klevan et al. (2008). Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Christian A. Vedeler; Elling Ulvestad et al. (2005). High dose methylprednisolone induces FcgammaR1 on granulocytes in MS-patients. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (1999). Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. (ekstern lenke)
• O Torkildsen; Øivind Fredvik Torkildsen; Egil Utsi et al. (2005). Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. (ekstern lenke)
• Sonia Gavasso; Ottar Nygård; Eva Kristine Ringdal Pedersen et al. (2005). Fc gamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. (ekstern lenke)
• Ann Cathrine Kroksveen; Elise Aasebø; Heidrun Vethe et al. (2013). Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. (ekstern lenke)
• Sonia Gavasso; Øivind Torkildsen; Tove Helene Marøy et al. (2012). Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. (ekstern lenke)
• Øivind Fredvik Torkildsen; Jan Harald Aarseth; Espen Benjaminsen et al. (2014). Month of birth and risk of multiple sclerosis: confounding and adjustments. (ekstern lenke)
• Øivind Fredvik Torkildsen; Christian A. Vedeler; Harald Inge Nyland et al. (2006). Fc gamma R and multiple sclerosis: an overview. (ekstern lenke)
• Sonia Gavasso; Kjell-Morten Myhr; Christian A. Vedeler (2006). Multiplexed phosphoprotein analysis in immune cells. (ekstern lenke)
• Kjell-Morten Myhr; Nina Grytten; Jan Harald Aarseth et al. (2006). The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis Registry - a resource for clinical practice and research. (ekstern lenke)
• Julie Dahl; Kjell-Morten Myhr; Anne Kjersti Daltveit et al. (2005). Pregnancy, delivery, and birth outcome in women with multiple sclerosis. (ekstern lenke)
• S Sawcer; G Hellenthal; M Pirinen et al. (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. (ekstern lenke)
• H Naess; Harald Inge Nyland; L Thomassen et al. (2004). Long-term outcome of cerebral infarction in young adults. (ekstern lenke)
• Espen Benjaminsen; Kjell-Morten Myhr; Nina Grytten et al. (2019). Validation of the multiple sclerosis diagnosis in the Norwegian Patient Registry. (ekstern lenke)
• Solveig Glad; Harald Inge Nyland; Kjell-Morten Myhr (2006). Benign multiple sclerosis. (ekstern lenke)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. (ekstern lenke)
• Kristin Wesnes; Kjell-Morten Myhr; Trond Riise et al. (2017). Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study. (ekstern lenke)
• Ellen Skorve; Astri Lundervold; Øivind Torkildsen et al. (2019). The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS). (ekstern lenke)
• Halvor Næss; Harald Inge Nyland; Lars Thomassen et al. (2005). Mild depression in young adults with cerebral infarction at long-term follow-up: A population-based study. (ekstern lenke)
• Sveinung Fjær; Lars Bø; Kjell-Morten Myhr et al. (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. (ekstern lenke)
• Anette Susanne Bøe Wolff; Kjell-Morten Myhr; Christian A. Vedeler et al. (2007). Fc gamma receptor polymorphisms are not associated with autoimmune Addison's disease. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Association of adverse childhood experiences with the development of multiple sclerosis. (ekstern lenke)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. (ekstern lenke)
• Hanne Marie Lunde; Tommy Frøseth Aae; William Indrevåg et al. (2012). Poor Sleep in Patients with Multiple Sclerosis. (ekstern lenke)
• Halvor Næss; Harald Inge Nyland; Lars Thomassen et al. (2005). Fatigue at long-term follow-up in young adults with cerebral infarction. (ekstern lenke)
• Halvor Næss; Ulrike Waje-Andreassen; Lars Thomassen et al. (2005). Do all young ischemic stroke patients need long-term secondary preventive medication?. (ekstern lenke)
• A. Glaser; A Stahmann; Tobias Meissner et al. (2018). Multiple sclerosis registries in Europe – An updated mapping survey. (ekstern lenke)
• Hanne Marie Lunde; Wenche Telstad; Nina Agnethe Grytten et al. (2014). Employment among patients with multiple sclerosis-A population study. (ekstern lenke)
• Maurizio A. Leone; Nadia Barizzone; Federica Esposito et al. (2013). Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. (ekstern lenke)
• Christina Heidemann Sundal; Matt C. Baker; Virginija Danylaité Karrenbauer et al. (2015). Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. (ekstern lenke)
• Agnes Elisabeth Nystad; Stig Wergeland; Lage Aksnes et al. (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Stig Wergeland (2014). Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. (ekstern lenke)
• Alok Bhan; Cecilie Jacobsen; Ingvild Dalen et al. (2023). Neurofilament and Brain Atrophy and Their Association with Cognition in Multiple Sclerosis: A 10-Year Follow-Up Study. (ekstern lenke)
• Bjørn Svendsen; Kjell-Morten Myhr; Harald Inge Nyland et al. (2012). The cost of multiple sclerosis in Norway. (ekstern lenke)
• Elise Aasebø; Jill Anette Opsahl; Yngvild Bjørlykke et al. (2014). Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. (ekstern lenke)
• Øivind Fredvik Torkildsen; Linn Anne Brunborg; Frits Alan Thorsen et al. (2009). Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. (ekstern lenke)
• Inger-Lise Mero; Åslaug Rudjord Lorentzen; CATHRINE SMESTAD et al. (2010). A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. (ekstern lenke)
• Jan-Lukas Førde; Lars Herfindal; Kjell-Morten Myhr et al. (2023). Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro. (ekstern lenke)
• Inger-Lise Mero; Marte Wendel Gustavsen; Hanne Skarpodde Sæther et al. (2013). Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. (ekstern lenke)
• Monica Nortvedt; Trond Riise; Jannicke Frugård et al. (2007). Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. (ekstern lenke)
• Anke E. Hensiek; Shaun Robert Seaman; Lisa F. Barcellos et al. (2007). Familial effects on the clinical course of multiple sclerosis. (ekstern lenke)
• J Dahl; KM Myhr; Anne Kjersti Nesje Daltveit et al. (2008). Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. (ekstern lenke)
• Nina Agnethe Grytten; Stein Atle Lie; Jan Harald Aarseth et al. (2008). Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. (ekstern lenke)
• Ludwig Kappos; Gilles Edan; Mark S. Freedman et al. (2016). The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. (ekstern lenke)
• Astrid Guldbrandsen; Heidrun Vethe; Yehia Mohamed Mokhtar Farag et al. (2014). In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). (ekstern lenke)
• Xinhua Yu; Dirk Koczan; Anna-Maija Sulonen et al. (2008). mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis. (ekstern lenke)
• Eystein Oveland; Agnes Elisabeth Nystad; Frode Berven et al. (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. (ekstern lenke)
• Tarja Anniki Rajalahti Kvalheim; Ann Cathrine Kroksveen; Reidar Arneberg et al. (2010). A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. (ekstern lenke)
• Andrea Kyvik Habbestad; Johannes Sverre Willumsen; Jan Harald Aarseth et al. (2023). Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. (ekstern lenke)
• Jonatan Salzer; Kjell-Morten Myhr (2013). Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No. (ekstern lenke)
• Øivind Torkildsen; Kristin Ingeleiv Løken-Amsrud; Stig Wergeland et al. (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. (ekstern lenke)
• Giulio Disanto; R Adiutori; V Martinelli et al. (2016). Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. (ekstern lenke)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2025). High-dimensional Immune Profiling Following Autologous Hematopoietic Stem Cell Transplantation in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Hilde Marie Torgauten; Therese Bredholt Onyango; Sonja Ljostveit et al. (2024). Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. (ekstern lenke)
• Per Soelberg Sørensen; Poul Erik Hyldgaard Jensen; Aiden Haghikia et al. (2011). Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. (ekstern lenke)
• Tori Smedal; Hilde Haukelid Johansen; Kjell-Morten Myhr et al. (2010). Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29). (ekstern lenke)
• Ann Cathrine Kroksveen; Jacob D. Jaffe; Elise Aasebø et al. (2015). Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. (ekstern lenke)
• SE Baranzini; E.G. Celius; I Elovaara et al. (2013). Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. (ekstern lenke)
• Cecilie Jacobsen; Robert Zivadinov; Kjell-Morten Myhr et al. (2021). Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.. (ekstern lenke)
• Thomas Berger; Irina Elovaara; Sten Fredrikson et al. (2016). Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts. (ekstern lenke)
• G Comi; V Martinelli; M Rodegher et al. (2009). Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. (ekstern lenke)
• Maria Nordheim Alme; Agnes Elisabeth Nystad; Lars Bø et al. (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. (ekstern lenke)
• PS Sorensen; SI Mellgren; A Svenningsson et al. (2009). NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. (ekstern lenke)
• Øivind Torkildsen; Stig Wergeland; Jacob Bakke et al. (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. (ekstern lenke)
• Agnes Elisabeth Nystad; Ragnhild Reehorst Lereim; Stig Wergeland et al. (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. (ekstern lenke)
• Jill Anette Opsahl; Marc Vaudel; Astrid Guldbrandsen et al. (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. (ekstern lenke)
• Gry Klevan; Cecilie Osman Jacobsen; Jan Harald Aarseth et al. (2014). Health related quality of life in patients recently diagnosed with multiple sclerosis. (ekstern lenke)
• Giammario Ragnedda; Stefania Leoni; Maria Parpinel et al. (2015). Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study. (ekstern lenke)
• Antonie Giæver Beiske; Halvor Næss; Jan Harald Aarseth et al. (2007). Health-related quality of life in secondary progressive multiple sclerosis. (ekstern lenke)
• Kirsten Lode; Jan Petter Larsen; Edvin Bru et al. (2007). Patient information and coping styles in multiple sclerosis. (ekstern lenke)
• Brit Ellen Rød; Stig Wergeland; Kjetil Lauvland Bjørnevik et al. (2023). Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. (ekstern lenke)
• Gerd Haga Bringeland; Kjell-Morten Myhr; Christian A. Vedeler et al. (2020). Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study. (ekstern lenke)
• Kjell-Morten Myhr; Øivind Fredvik Torkildsen (2020). Serum NFL levels should be used to monitor multiple sclerosis evolution - No.. (ekstern lenke)
• Monica W Nortvedt; Trond Riise; J Frugård et al. (2007). Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. (ekstern lenke)
• Ingrid Anne Lie; Emma Kerklingh; Kristin Wesnes et al. (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. (ekstern lenke)
• Trond Trætteberg Serkland; Silje Skrede; Erik Ingmar Hallin et al. (2025). Pharmacokinetic-pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval. (ekstern lenke)
• Hilde Marie Torgauten; Kjell-Morten Myhr; Stig Wergeland et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. (ekstern lenke)
• Åslaug Rudjord Lorentzen; Espen Melum; Eva Ellinghaus et al. (2010). Association to the Glypican-5 gene in multiple sclerosis. (ekstern lenke)
• An Goris; Ine Pauwels; Marte Wendel Gustavsen et al. (2015). Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. (ekstern lenke)
• Ashley H. Beecham; NA Patsopoulos; DK Xifara et al. (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. (ekstern lenke)
• Solveig Bergljot Glad; Harald Inge Nyland; Jan Harald Aarseth et al. (2009). Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. (ekstern lenke)
• Halvor Næss; Antonie Giæver Beiske; Kjell-Morten Myhr (2008). Quality of life among young patients with ischaemic stroke compared with patients with multiple sclerosis. (ekstern lenke)
• Halvor Næss; Solveig B Glad; Anette Storstein et al. (2010). Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. (ekstern lenke)
• Egil Rørvik Røsjø; Jonas Christoffer Lindstrøm; Trygve Holmøy et al. (2020). Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Ng'weina Francis Magitta; Anette Susanne Bøe Wolff; Stefan Johansson et al. (2009). A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. (ekstern lenke)
• Henning Kristian Olberg; Geir Egil Eide; Rebecca Jane Cox et al. (2018). Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. (ekstern lenke)
• Maria Ban; Stacy Caillier; Inger-Lise Mero et al. (2013). No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Kjell-Morten Myhr; Vegard Skogen et al. (2020). Tenofovir as a treatment option for multiple sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Harald Inge Nyland; Helge Myrmel et al. (2008). Epstein-Barr virus reactivation and multiple sclerosis. (ekstern lenke)
• Gerd Haga Bringeland; Nello Blaser; Kjell-Morten Myhr et al. (2021). Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic. (ekstern lenke)
• Cecilie Jacobsen; Robert Zivadinov; Kjell-Morten Myhr et al. (2020). Brain atrophy and employment in multiple sclerosis patients: a 10-year follow-up study. (ekstern lenke)
• Hanne Marie Lunde; Jörg Assmus; Kjell-Morten Myhr et al. (2017). Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. (ekstern lenke)
• Margitta Theodora Kampman; Jan Harald Aarseth; Nina Agnethe Grytten et al. (2013). Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. (ekstern lenke)
• Kirsten Lode; Edvin Bru; Gry Klevan et al. (2010). Coping with multiple sclerosis: a 5-year follow-up study. (ekstern lenke)
• Akash Kapali; Anne Kjersti Nesje Daltveit; Kjell-Morten Myhr et al. (2023). Childbirth delivery mode and the risk of multiple sclerosis: A prospective population-based study. (ekstern lenke)
• Henning Kristian Olberg; Rebecca Jane Cox; Jane Kristin Nøstbakken et al. (2014). Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. (ekstern lenke)
• Pameli Datta; Hanne F Harbo; Lars P. Ryder et al. (2007). A follow-up study of Nordic multiple sclerosis candidate gene regions. (ekstern lenke)
• E. Coerver; L. Schoof; L. Hogenboom et al. (2024). The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. (ekstern lenke)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2022). Cancer related mortality in multiple sclerosis. A population based cohort study. (ekstern lenke)
• Katja Marja Hakkarainen; Rosa Juuti; Sarah Burkill et al. (2020). Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. (ekstern lenke)
• Tarja Rajalahti; Reidar Arneberg; Ann Cathrine Kroksveen et al. (2009). Discriminating Variable Test and Selectivity Ratio Plot: Quantitative Tools for Interpretation and Variable (Biomarker) Selection in Complex Spectral or Chromatographic Profiles. (ekstern lenke)
• Mechelli Rosella; Umeton Renato; Claudia Policano et al. (2013). A ‘‘candidate-interactome’’ aggregate analysis of genome-wide association data in multiple sclerosis. (ekstern lenke)
• Gerd Haga Bringeland; Lucius Bader; Nello Blaser et al. (2019). Optimization of receptor occupancy assays in mass cytometry: Standardization across channels with QSC beads. (ekstern lenke)
• Kjell-Morten Myhr (2008). Diagnosis and treatment of multiple sclerosis. (ekstern lenke)
• Sveinung Fjær; Lars Bø; Arvid Lundervold et al. (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. (ekstern lenke)
• Kristin Ingeleiv Løken-Amsrud; Kjell-Morten Myhr; Søren Jacob Bakke et al. (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. (ekstern lenke)
• Ellen Skorve; Astri J. Lundervold; Øivind Torkildsen et al. (2022). Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS – A longitudinal correlation study. (ekstern lenke)
• Tori Smedal; Hildegunn Lygren; Kjell-Morten Myhr et al. (2006). Balance and gait improved in patients with MS after physiotherapy based on the Bobath concept. (ekstern lenke)
• Gerd Haga Bringeland; Nello Blaser; Kjell-Morten Myhr et al. (2020). Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy. (ekstern lenke)
• Inger-Lise Mero; CATHRINE SMESTAD; Benedicte Alexandra Lie et al. (2012). Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course. (ekstern lenke)
• O Andersen; I Elovaara; M Farkkila et al. (2004). Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Kjell-Morten Myhr et al. (2008). The cuprizone model for demyelination. (ekstern lenke)
• Nina Grytten; Jan Harald Aarseth; Hanne Marie Lunde et al. (2016). A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Lars Bø (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. (ekstern lenke)
• Silje Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2016). No association of tobacco use and disease activity in multiple sclerosis. (ekstern lenke)
• Sarah Burkill; Pia Vattulainen; Yvonne Geissbuehler et al. (2019). The Association Between Exposure to Interferon-Beta During Pregnancy and Birth Measurements in Offspring of Women With Multiple Sclerosis. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Trond Riise; Inger Bostrom et al. (2016). Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. (ekstern lenke)
• Christopher Storm Larsen; Kjell-Morten Myhr; Elisabeth Farbu et al. (2019). Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial. (ekstern lenke)
• Halvor Næss; Ulrike Waje-Andreassen; Lars Thomassen et al. (2006). Health-related quality of life among young adults with ischemic stroke on long-term follow-up. (ekstern lenke)
• Trond Riise; Jorunn Kirkeleit; Jan Harald Aarseth et al. (2011). Risk of MS is not associated with exposure to crude oil, but increases with low level of education. (ekstern lenke)
• Maura Pugliatti; Ilaria Casetta; Jelena Drulovic et al. (2012). A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q). (ekstern lenke)
• Stig Wergeland; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. (ekstern lenke)
• Marte Wendel Gustavsen; Marte K Viken; Elisabeth Gulowsen Celius et al. (2014). Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. (ekstern lenke)
• Espen Benjaminsen; Kjell-Morten Myhr; Karl Bjørnar Alstadhaug (2017). The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway. (ekstern lenke)
• Brit Ellen Rød; Einar August Høgestøl; Øivind Torkildsen et al. (2025). Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation. (ekstern lenke)
• Ragnhild Reehorst Lereim; Petra Nytrova; Astrid Guldbrandsen et al. (2024). Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis. (ekstern lenke)
• Sandra Magalhaes; Maura Pugliatti; Ilaria Casetta et al. (2015). The EnvIMS study: Design and methodology of an international case-control study of environmental risk factors in multiple sclerosis. (ekstern lenke)
• Nina Karin Aarskog; Tove Marøy; Kjell-Morten Myhr et al. (2009). Antibodies against interferon-beta in multiple sclerosis. (ekstern lenke)
• Julie Dahl; Kjell-Morten Myhr; Anne Kjersti Nesje Daltveit et al. (2007). Is smoking an extra hazard in pregnant MS women? Findings from a population-based registry in Norway. (ekstern lenke)
• Ann Cathrine Kroksveen; Astrid Guldbrandsen; Christian A. Vedeler et al. (2012). Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. (ekstern lenke)
• Peter Andreas Vold Lossius; Trond Riise; Maura Pugliatti et al. (2014). Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. (ekstern lenke)
• Trygve Holmøy; Kristin Ingeleiv Løken-Amsrud; Jacob Bakke et al. (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. (ekstern lenke)
• Maria Therese Fossum; Hilde Marie Torgauten; Jan Harald Aarseth et al. (2025). Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety. (ekstern lenke)
• AB Oturai; LP Ryder; S Fredrikson et al. (2004). Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. (ekstern lenke)
• Nina Agnethe Grytten; Solveig B. Glad; Jan Harald Aarseth et al. (2006). A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. (ekstern lenke)
• Johannes Sverre Willumsen; Jan Harald Aarseth; Kjell-Morten Myhr et al. (2020). High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950–2018. (ekstern lenke)
• Halvor Næss; Endre Sundal; Kjell-Morten Myhr et al. (2010). Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. (ekstern lenke)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. (ekstern lenke)
• H Naess; Harald Inge Nyland; L Thomassen et al. (2004). Etiology of and risk factors for cerebral infarction in young adults in western Norway: a population-based case-control study. (ekstern lenke)
• Marianna Cortese; Trond Riise; Kjetil Lauvland Bjørnevik et al. (2016). Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom. (ekstern lenke)
• Hilde Norborg; Trond Riise; Kjell-Morten Myhr et al. (2021). Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. (ekstern lenke)
• Ng’weina Francis Magitta; AS Bøe; S Johansson et al. (2008). A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. (ekstern lenke)
• Erik Ingmar Hallin; Trond Trætteberg Serkland; Kjell-Morten Myhr et al. (2022). Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. (ekstern lenke)
• Brit Ellen Rød; Øivind Torkildsen; Kjell-Morten Myhr et al. (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. (ekstern lenke)
• R Goulden; Trond Riise; Kjell-Morten Myhr et al. (2016). Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case-control study. (ekstern lenke)
• Monica W Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2001). Quality of life as a predictor for change in disability in MS reply (letter). (ekstern lenke)
• Kirsten Lode; Edvin Bru; G. Klevan et al. (2009). Depressive symptoms and coping in newly diagnosed patients with multiple sclerosis. (ekstern lenke)
• Tori Smedal; Antonie Giæver Beiske; Solveig Bergliot Glad et al. (2011). Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance. (ekstern lenke)
• AG Beiske; Elisabeth Karin Svensson; I Sandanger et al. (2008). Depression and anxiety amongst multiple sclerosis patients. (ekstern lenke)
• Øivind Fredvik Torkildsen; Linn Anne Brunborg; Anne Marita Milde et al. (2009). A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. (ekstern lenke)
• Eystein Oveland; Intakhar Ahmad; Ragnhild Reehorst Lereim et al. (2021). Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. (ekstern lenke)
• Jakob Rishovd Karlowicz; Mattias Klakegg; Jan Harald Aarseth et al. (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. (ekstern lenke)
• Johannes Sverre Willumsen; Nina Grytten; Jan Harald Aarseth et al. (2022). Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: A registry-based linkage study. (ekstern lenke)
• Kjell-Morten Myhr; Trond Riise; C Vedeler et al. (2001). Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. (ekstern lenke)
• Monica W Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2001). Reduced quality of life among MS patients with sexual disturbance and bladder dysfunction. (ekstern lenke)
• Pankaj Keshari; Hanne Flinstad Harbo; Kjell-Morten Myhr et al. (2016). Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood. (ekstern lenke)
• Ingrid Anne Lie; Kristin Wesnes; Silje Agnethe Stokke Kvistad et al. (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Helga Westerlind; Kerstin Imrell; Ryan Ramanujam et al. (2015). Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. (ekstern lenke)
• Kjell-Morten Myhr; Nina Agnethe Grytten; Øivind Torkildsen et al. (2012). A need for national registries and international collaborative research in multiple sclerosis. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2000). Quality of life as a predictor for change in disability in multiple sclerosis. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2000). Performens of the SF-36, SF-12 and RAND-36 summary scales in a multiple sclerosis population. (ekstern lenke)
• Ola Nakken; Trygve Holmøy; Hein Stigum et al. (2022). Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study. (ekstern lenke)
• Silje Agnethe Stokke; Anne Kristine Lehmann; Linn Trovik et al. (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. (ekstern lenke)
• Kristin Wesnes; Trond Riise; Ilaria Casetta et al. (2015). Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. (ekstern lenke)
• Ingrid Anne Lie; Sezgi Kacar; Kristin Wesnes et al. (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. (ekstern lenke)
• M. Pugliatti; HF Harbo; H.F. Harbo et al. (2008). Environmental risk factors in multiple sclerosis. (ekstern lenke)
• Nina Agnethe Grytten; Øivind Torkildsen; Jan Harald Aarseth et al. (2013). Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. (ekstern lenke)
• Jurate Saltyte Benth; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2012). Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients. (ekstern lenke)
• Bjørn Svendsen; Nina Grytten; Lars Bø et al. (2018). The economic impact of multiple sclerosis to the patients and their families in Norway. (ekstern lenke)
• Kristin Ingeleiv Løken-Amsrud; Trygve Holmøy; Søren J. Bakke et al. (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. (ekstern lenke)
• Mitja Mitrovic; Nikolaos A. Patsopoulos; Ashley H. Beecham et al. (2018). Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. (ekstern lenke)
• Tarja Rajalahti; Reidar Arneberg; Frode Berven et al. (2009). Biomarker discovery in mass spectral profiles by means of selectivity ratio plot. (ekstern lenke)
• Øivind Fredvik Torkildsen; Nina Agnethe Grytten; Kjell-Morten Myhr (2007). Immunomodulatory treatment of multiple sclerosis in Norway. (ekstern lenke)
• Åslaug R Lorentzen; Cathrine Smestad; Benedicte A Lie et al. (2008). The SH2D2A gene and susceptibility to multiple sclerosis. (ekstern lenke)
• Kirsten Lode; Edvin Bru; Gry Klevan et al. (2009). Depressive symptoms and coping in newly diagnosed patients with multiple sclerosis. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Trond Riise; Ilaria Casetta et al. (2014). Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. (ekstern lenke)
• Hanne Flinstad Harbo; Maria Elena Riccio; Åslaug Rudjord Lorentzen et al. (2010). Norwegian Sami differs significantly from other Norwegians according to their HLA profile. (ekstern lenke)
• Ellen Skorve; Astri Lundervold; Øivind Torkildsen et al. (2020). A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Christine Stansberg; Solveig Mjelstad Angelskår et al. (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. (ekstern lenke)
• Trygve Holmøy; Øivind Torkildsen; Kjell-Morten Myhr (2017). An update on cladribine for relapsing-remitting multiple sclerosis. (ekstern lenke)
• Kjell-Morten Myhr (2009). Vitamin D treatment in multiple sclerosis. (ekstern lenke)
• Sonia Gavasso; Bjørn Tore Gjertsen; Endre Anderssen et al. (2012). Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. (ekstern lenke)
• Tomas Olsson; Anat Achiron; Lars Alfredsson et al. (2013). Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. (ekstern lenke)
• Helle Bach Søndergaard; Finn Sellebjerg; Jan Hillert et al. (2011). Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. (ekstern lenke)
• Tori Smedal; Kjell-Morten Myhr; Jan Harald Aarseth et al. (2011). The influence of warm versus cold climate on the effect of physiotherapy in multiple sclerosis. (ekstern lenke)
• Geir Risberg; Jan Harald Aarseth; Harald Inge Nyland et al. (2011). Prevalence and incidence of multiple sclerosis in Oppland County – a cross-sectional population-based study in a landlocked county of Eastern Norway. (ekstern lenke)
• PS Sorensen; Svein Ivar Mellgren; A Svenningsson et al. (2009). NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. (ekstern lenke)

Studieprotokoll

• Lisa G. Schoof; Brit Ellen Rød; Sahla El Mahdaoui et al. (2025). Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysis. (ekstern lenke)

Kasusrapport

• Øivind Fredvik Grytten Torkildsen; Alla Nikolajevna S Bru; Gry Inger N Behzadi et al. (2026). Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. (ekstern lenke)

Konferanseabstrakt

• Tori Smedal; Kyrre Breivik; Roshan das Nair et al. (2025). Evaluating the response categories of the Multiple Sclerosis Impact Scale-29: A Rasch Analysis. (ekstern lenke)
• Åslaug Rudjord Lorentzen; Espen Melum; Eva Buchert et al. (2010). Trend of association to the Glypican 5 gene region to multiple sclerosis. (ekstern lenke)
• SS Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. (ekstern lenke)
• HF Harbo; Egil Utsi; Margitta Theodora Kampman et al. (2006). Low prevalence of multiple sclerosis and the HLA CR15-DQ6 halotype in Sami. (ekstern lenke)
• Sonia Gavasso; Tove Helene Marøy; Ellen Færgestad Mosleth et al. (2012). Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. (ekstern lenke)
• Jens Kuhle; R Dobson; JP Bestwick et al. (2013). Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. (ekstern lenke)
• Tori Smedal; Kjell-Morten Myhr; Bente Gjelsvik et al. (2008). Gait and balance improved in patients with multiple sclerosis after inpatient physiotherapy. (ekstern lenke)
• Kristin Wesnes; Trond Riise; M Pugliatti et al. (2012). Overweight as a risk factor for multiple sclerosis. (ekstern lenke)
• Tarja Rajalahti; Reidar Arneberg; Frode Berven et al. (2008). Biomarker discovery from mass spectral profiles: A combined proteomics and multivariate analysis. (ekstern lenke)
• J Dahl; KM Myhr; Anne Kjersti Daltveit et al. (2006). Pregnancy, delivery and birth outcome in mothers prior to debut of multiple sclerosis. (ekstern lenke)
• Antonie Giæver Beiske; Halvor Næss; Jan Harald Aarseth et al. (2006). Health-related quality of life in secondary progressive multiple sclerosis. (ekstern lenke)
• Åslaug Rudjord Lorentzen; EG Celius; P Ekstrom et al. (2005). The CD28/CTLA4/ICOS gene region does not show assosiation in Norwegian multiple sclerosis patients. (ekstern lenke)
• Stig Wergeland; Øivind Fredvik Torkildsen; Kjell-Morten Myhr et al. (2009). Histopathological characterisation of the cuprizone model for demyelination. (ekstern lenke)
• M Pugliatti; M. Pugliatti; I Casetta et al. (2009). International case control study on risk factors for multiple sclerosis (MS): pilot testing the questionnaire. (ekstern lenke)
• AR Lorentzen; CATHRINE SMESTAD; Per Olaf Ekstrøm et al. (2006). The role of SH2D2A gene polymorphisms in multiple sclerosis. (ekstern lenke)
• Bjørn-Yngvar Nordvåg; Tomm Bernklev; Ellen Margrethe Slevolden et al. (2012). Norwegian quality registry for biological drugs: the NOKBIL project. (ekstern lenke)
• Sonia Gavasso; Jørn Skavland; Bjørn Tore Gjertsen et al. (2008). Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. (ekstern lenke)
• Tarja Rajalahti; Reidar Arneberg; Frode Berven et al. (2008). Early diagnosis and biomarker discovery from mass spectral profiles: application to multiple sclerosis. (ekstern lenke)
• Maura Pugliatti; Ilaria Casetta; Paola Cossu et al. (2008). An international case-control study of risk factors for multiple sclerosis. (ekstern lenke)
• Solveig B Glad; Jan Harald Aarseth; Harald Inge Nyland et al. (2010). The definition of benign multiple sclerosis: a methodical approach. (ekstern lenke)
• Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Anne Marita Milde et al. (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. (ekstern lenke)
• Maura Pugliatti; Ilaria Casetta; Paola Cossu et al. (2008). Acceptability and cross-cultural feasibility of it self-administered questionnaire on past exposure to putative environmental risk factors for multiple sclerosis. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Trond Riise; Kristin Wesnes et al. (2012). An age at exposure effect between sun exposure and the risk of MS in Norway and Italy. (ekstern lenke)
• Hanne Flinstad Harbo; E Utsi; Åslaug Rudjord Lorentzen et al. (2006). Low prevalence of multiple sclerosis in a Sami population is related to low frequency of the disease-associated HLA DR15-DQ6 haplotype. (ekstern lenke)
• K J Oen; Kjell-Morten Myhr; A B R Skar et al. (2012). WalkAide - A multidisciplinary model for adjustment and evaluation. (ekstern lenke)
• Jorunn Kirkeleit; Trond Riise; Jan Harald Aarseth et al. (2011). The Risk of Multiple Sclerosis Among Petroleum Workers Exposed to Crude Oil and Other Hydrocarbons. (ekstern lenke)
• Julie Dahl; Kjell-Morten Myhr; Anne Kjersti Daltveit et al. (2007). Perinatal factors and later development of multiple sclerosis. (ekstern lenke)
• Nina Agnethe Grytten; Øivind Fredvik Torkildsen; Jan Harald Aarseth et al. (2007). Increasing prevalence of multiple sclerosis in the elderly in western Norway. (ekstern lenke)
• Antonie Giæver Beiske; Tori Smedal; Solveig B. Glad et al. (2007). Individualised physiotherapy improved fatigue score in patients with multiple sclerosis. (ekstern lenke)
• Julie Dahl; Kjell-Morten Myhr; Anne Kjersti Daltveit et al. (2007). Smoking habits in pregnant MS women. (ekstern lenke)
• Christine Stansberg; S Angelska; Evert-Jan Kooi et al. (2009). Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. (ekstern lenke)
• Tori Smedal; Antonie Giæver Beiske; Jan Harald Aarseth et al. (2009). Fatigue in multiple sclerosis is associated with self-perceived health, but less with physical performance. (ekstern lenke)
• Hanne Marie Lunde; Tommy F Aae; William Indrevåg et al. (2012). Poor sleep in patients with multiple sclerosis. (ekstern lenke)
• Grytten Nina; Espen Benjaminsen; Elisabeth Gulowsen Celius et al. (2017). Cancer risk in multiple sclerosis. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. (ekstern lenke)
• Kjell-Morten Myhr (2011). VITAMIN D, LIFESTYLE FACTORS AND RISK OF MULTIPLE SCLEROSIS. (ekstern lenke)
• Åslaug Rudjord Lorentzen; C. Smestad; PO Ekstrom et al. (2006). The role of SH2D2A gene polymorphisms in development of multiple sclerosis. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Shamundeeswari Anandan; Karina Maciak; Regina Breinbauer et al. (2025). Brain-derived blood biomarkers in multiple sclerosis—current trends and beyond. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Lars Bø et al. (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. (ekstern lenke)
• Ingrid Anne Lie; Merlin M. Weeda; Rozemarijn M. Mattiesing et al. (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. (ekstern lenke)
• Hanne Marie Lunde; Bjørn Bjorvatn; Kjell-Morten Myhr et al. (2013). Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. (ekstern lenke)
• K M Myhr; Svein Ivar Mellgren (2009). Corticosteroids in the treatment of multiple sclerosis. (ekstern lenke)
• Sharmilee Gnanapavan; Harald Hegen; Marwan Khalil et al. (2014). Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. (ekstern lenke)
• Karl Bjørnar Alstadhaug; Kjell-Morten Myhr; Christine Hanssen Rinaldo (2017). Progredierende multifokal leukoencefalopati. (ekstern lenke)
• Trygve Holmøy; Rune Alexander Høglund; Zsolt Illes et al. (2020). Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. (ekstern lenke)
• Franz Fazekas; Klaus Gehring; Paolo Gallo et al. (2015). Country break-out session highlights. (ekstern lenke)
• Kjell-Morten Myhr; Øivind Torkildsen; Peter Andreas Vold Lossius et al. (2019). B cell depletion in the treatment of multiple sclerosis. (ekstern lenke)
• Patrick Vermersch; Jiwon Oh; Mark Cascione et al. (2020). Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. (ekstern lenke)
• Kjell-Morten Myhr; Nina Grytten; Øivind Torkildsen et al. (2015). The Norwegian Multiple Sclerosis Registry and Biobank. (ekstern lenke)
• Nina Grytten; Øivind Torkildsen; Kjell-Morten Myhr (2015). Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. (ekstern lenke)
• Peter Flachenecker; Karoline Buckow; Maura Pugliatti et al. (2014). Multiple sclerosis registries in Europe - Results of a systematic survey. (ekstern lenke)
• Silje Agnethe Stokke; Stig Wergeland; Øivind Torkildsen et al. (2013). Neuromyelitis optica. (ekstern lenke)
• R Midgard; AG Beiske; EG Celius et al. (2003). New diagnostic criteria in multiple sclerosis. (ekstern lenke)
• Kristin Nielsen Varhaug; Øivind Torkildsen; Kjell-Morten Myhr et al. (2019). Neurofilament light chain as a biomarker in multiple sclerosis. (ekstern lenke)

Konferanseposter

• Alok Bhan; Cecilie Osman Jacobsen; Kirsten Lode et al. (2016). Neurofilament light chain and disease progression in MS. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2000). Livskvalitet og multippel sklerose. Betydningen av subjektive og objektive sykdomstegn for livskvaliteten til mennesker med multippel sklerose. (ekstern lenke)
• Kjell-Morten Myhr; Trond Riise; F Lillås et al. (2000). Result from design of a randomised, placebo-controlled, double blind trial in Norway. Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a. (ekstern lenke)
• Kjell-Morten Myhr; Trond Riise; Christian A Vedeler et al. (2000). Long-term prognosis in a incidence cohort of 219 multiple sclerosis patients from Hordaland county, Western Norway. (ekstern lenke)
• Kjell-Morten Myhr; Tove Helene Marøy; Sonia Gavasso et al. (2007). Nøytraliserende antistoffer mot interferon-beta ved Multippel Sclerose. (ekstern lenke)
• Sonia Gavasso; Nina Karin Aarskog; Kjell-Morten Myhr et al. (2004). Fc gamma receptor expression of peripheral leukocytes in Multiple Sclerosis patients treated with interferon-beta or glatiramer acetate.. (ekstern lenke)
• Kristin Wesnes; Trond Riise; Kjell-Morten Myhr et al. (2012). The relationship between body size and the risk of multiple sclerosis. -The EnvIMS study. (ekstern lenke)
• Kjell-Morten Myhr; Stephan Schuler; Karl Bjørnar Alstadhaug (2019). Long-term, real-world effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis (RRMS): data from ≥6 years in the TYSABRI® Observational Program (TOP) Nordic and global cohorts.. (ekstern lenke)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2000). Perfomance of the SF-12 Health Survey in a population of multiple sclerosis patients. (ekstern lenke)
• Trond Riise; Kjell-Morten Myhr; Ilaria Casetta et al. (2004). A multicentric case-control study on multiple sclerosis. (ekstern lenke)
• Marton König; Asia-Sophia Fumika Michaela Wolf; Anthony Ravussin et al. (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. (ekstern lenke)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2024). Short-Term and Long-Term Impact of Autologous Haematopoietic Stem Cell Transplantation on Immune Profiles in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Trond Trætteberg Serkland; Erik Ingmar Hallin; Kjell-Morten Myhr et al. (2022). LC-MS/MS quantification of ocrelizumab in the treatment of multiple sclerosis. (ekstern lenke)
• Harald Nyland; Monica W Nortvedt; Kjell-Morten Myhr et al. (2003). Pasienter med benign multippel sklerose har redusert helserelatert livskvalitet. (ekstern lenke)

Konferanseforedrag

• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (1999). Expanded Disability Status Scale scores and the Quality of Life of Multiple Sclerosis patients. An epidemiological study. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (1999). The quality of life of multiple sclerosis patients in a treatment trial with recombinant interferon-alfa-2a. (ekstern lenke)
• Trond Riise; Monica Wammen Nortvedt; Kjell-Morten Myhr et al. (1999). Lack of agreement between objective disease measures and the Quality of Life in a treatment trial in multiple sclerosis. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Trond Riise; Jorunn Kirkeleit et al. (2014). Level of education and multiple sclerosis risk after adjustment for known risk factors: the EnvIMS study. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2000). Livskvalitet hos multippel sklerose pasienter - en utfordring for sykepleien. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2000). Livskvalitet hos multippel sklerose pasienter. (ekstern lenke)
• Marianna Cortese; Trond Riise; Kjetil Lauvland Bjørnevik et al. (2015). Evidence of preclinical disease activity­ a prospective study on cognitive and physical performance prior to first symptom of multiple sclerosis. (ekstern lenke)
• Bjørn Svendsen; Kjell-Morten Myhr; Harald Nyland et al. (2006). Costs and quality of life in patients with multiple sclerosis in Norway compared to 9 other European countries. (ekstern lenke)
• Tarja Rajalahti; Reidar Arneberg; Kristian Flikka et al. (2007). Preteatment of Mass Spectral Profiles: Application to proteomic data. (ekstern lenke)
• Olav Martin Kvalheim; Tarja Rajalahti; Reidar Arneberg et al. (2007). Analysis of Proteomic Profiles. (ekstern lenke)
• Trond Trætteberg Serkland; Erik Ingmar Hallin; Kjell-Morten Myhr et al. (2022). Rituximab in the treatment of multiple sclerosis: A pharmacokinetic-pharmacodynamic model. (ekstern lenke)
• Olav Martin Kvalheim; Tarja Rajalahti; Reidar Arneberg et al. (2007). Target projection and proper data pre-treatment for the analysis of proteomic profiles. (ekstern lenke)
• Trond Riise; Monica Wammen Nortvedt; Kjell-Morten Myhr et al. (2000). Quality of life as a predictor for change in disability in multiple sclerosis. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (2000). Reduced quality of life among MS patients with sexual disturbance and bladder dysfunction. (ekstern lenke)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Margitta Theodora Kampman et al. (2015). Vitamin D og interferon-behandling ved multippel sklerose. (ekstern lenke)

Leserbrev

• Sreeram V Ramagopalan; Heather EC Hanwell; Gavin Giovannoni et al. (2010). Vitamin D-Dependent Rickets, HIA-DRB1, and the Risk of Multiple Sclerosis. (ekstern lenke)
• Antonie Giæver Beiske; Kjell-Morten Myhr (2006). Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. (ekstern lenke)
• Kjell-Morten Myhr (2010). K.-M. Myhr svarer. (ekstern lenke)
• Øivind Torkildsen; Jan Harald Aarseth; Elisabeth Gulowsen Celius et al. (2014). Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. (ekstern lenke)
• Trygve Holmøy; Kristin Ingeleiv Løken-Amsrud; Margitta Theodora Kampman et al. (2014). Re: Vitamin D-how much is enough, and is more better for your Health?. (ekstern lenke)
• Trygve Holmøy; Kjell-Morten Myhr; Lars Bø (2014). Re: Uetisk av nevrologene ikke å tilby pasienter med multippel sklerose cytostatikabehandling med autolog stamcellestøtte. (ekstern lenke)
• U Waje-Andreassen; Jostein Kråkenes; Elling Ulvestad et al. (2005). Response to: Interleukin-6 and acute ischaemic stroke. (ekstern lenke)
• Gro Owren Nygaard; Hilde Marie Torgauten; Lars Skattebøl et al. (2022). Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Pascal Brügger-Synnes et al. (2024). Antiviral therapy with tenofovir in MS. (ekstern lenke)
• Nina Grytten; Øivind Torkildsen; Kjell-Morten Myhr (2015). Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'. (ekstern lenke)
• Ingrid Anne Lie; Brit Ellen Rød; Silje Agnethe Stokke et al. (2023). Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. (ekstern lenke)

Fagartikkel

• Øivind Torkildsen; Trygve Holmøy; Kjell-Morten Myhr (2018). Severe multiple sclerosis reactivation after gonadotropin treatment. (ekstern lenke)
• Monica Wammen Nortvedt; Trond Riise; Kjell-Morten Myhr et al. (1995). Forskning på livskvalitet, multippel sklerose. (ekstern lenke)
• Inger Marie Skoie; Jan Gunnar Skogås; Thomas Langø et al. (2023). Nye sentre skal gi flere kliniske studier i Norge. (ekstern lenke)

Populærvitenskapelig artikkel

• Kjell-Morten Myhr (2005). Har omega-3 noen effekt på MS?. (ekstern lenke)

Fremhevet artikkel i media

• Øivind Torkildsen; Brit Ellen Rød; Lars Bø et al. (2022). Amming og behandling av multippel sklerose. (ekstern lenke)
• Joel Glover; Ole-Bjørn Tysnes; Kjell-Morten Myhr et al. (2019). Hvor står ALS-forskningen i Norge?. (ekstern lenke)

Vitenskapelig bokkapittel

• Kjell-Morten Myhr (2015). Neuromyelitis Optica. (ekstern lenke)
• Kjell-Morten Myhr (2015). Multiple Sclerosis. (ekstern lenke)
• Kjell-Morten Myhr; Øivind Torkildsen; Lars Bø (2014). Multippel Sklerose. (ekstern lenke)
• Kjell-Morten Myhr; Harald Inge Nyland (2007). Multippel sklerose. (ekstern lenke)

Doktorgradsavhandling

• Marianna Cortese; Kjell-Morten Myhr (2017). The timing of environmental risk factors and prodromal signs of multiple sclerosis. (ekstern lenke)
• Sveinung Fjær; Kjell-Morten Myhr (2016). Magnetization Transfer Ratio in Experimental Models of Multiple Sclerosis. (ekstern lenke)
• Nina A. Grytten Torkildsen; Harald Inge Nyland; Kjell-Morten Myhr et al. (2008). Multiple Sclerosis in Western Norway. Incidence, prevalence, survival and ‘the lived experience'. (ekstern lenke)

Forskningsrapport

• Bjørn Svendsen; Kjell-Morten Myhr; Harald Nyland et al. (2006). The cost of multiple sclerosis in Norway ? (and how certain can we be?). (ekstern lenke)
• Bjørn Svendsen; Jan Harald Aarseth; Harald Nyland et al. (2007). Økonomisk analyse av behandling av MS-pasienter med Tysabri® i Norge. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.